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Background: Studies have linked asthma death to either increased or decreased use of medical services.
Methods: A population based case-control study of asthma deaths in 1994–8 was performed in 22
English, six Scottish, and five Welsh health authorities/boards. All 681 subjects who died were under the
age of 65 years with asthma in Part I on the death certificates. After exclusions, 532 hospital controls were
matched to 532 cases for age, district, and date of asthma admission/death. Data were extracted blind
from primary care records.
Results: The median age of the subjects who died was 53 years; 60% of cases and 64% of controls were
female. There was little difference in outpatient attendance (55% and 55%), hospital admission for asthma
(51% and 54%), and median inpatient days (20 days and 15 days) in the previous 5 years. After mutual
adjustment and adjustment for sex, using conditional logistic regression, three variables were
independently associated with asthma death: fewer general practice contacts (odds ratio 0.82 (95%
confidence interval (CI) 0.74 to 0.91) per 5 contacts) in the previous year, more home visits (1.14 (95% CI
1.08 to 1.21) per visit) in the previous year, and fewer peak expiratory flow recordings (0.83 (95% CI
0.74 to 0.92) per occasion) in the previous 3 months. These associations were similar after adjustment for
markers of severity, psychosocial factors, systemic steroids, short acting bronchodilators and antibiotics,
although the association with peak flow was weakened and just lost significance.
Conclusion: Asthma death is associated with less use of primary care services. Both practice and patient factors
may be involved and a better understanding of these may offer possibilities for reducing asthma death.
I
n England and Wales, mortality from asthma halved
between 1986 and 1999 but, despite incentives in general
practice and continued improvements in asthma care, 2387
people under the age of 65 years died from asthma in the
5 years between 1994 and 1998.1 Many of these asthma
deaths were considered preventable by a number of UK
confidential enquiries which all pointed to underuse of
medical services as a possible contributory factor.2–8
The risk of asthma death or near fatal episodes and use of
medical services have been investigated in previous case-
control studies.9–14 Some found no association between
asthma death (and near fatal episodes) and use of medical
services11 14 while others linked death to increased9 or
decreased12 use of services. Against this background and to
redress shortcomings of previous investigations, we carried
out a large population based study of cases (asthma deaths)
and controls and their use of health services in the previous
5 years.
METHODS
Cases and controls
The study of asthma deaths between 1994 and 1998
(inclusive) was undertaken in the same regions of England,
Scotland, and Wales as the confidential enquiries into
asthma deaths. The study areas, covering 27% of the British
population, were East Anglia, West Midlands, Northampton
and Kettering, North Essex, Northern Region (Cumbria and
districts north of the Tyne), all Wales and Scotland (Glasgow,
Lothian, Argyle and Clyde, Lanarkshire, Ayrshire and Arran,
and Forth Valley). In Scotland the time period was reduced to
3 years (1996–8) because of delays in ethics approval and
destruction of most of the pre-1996 records.
The Office for National Statistics and the General Register
Office provided lists of asthma deaths in subjects under the
age of 65 years (9th revision of the international classifica-
tion of diseases (ICD9 493)). The entry criteria were that
asthma was mentioned in Part I of the death certificate, that
the underlying cause was not cancer or other conditions
unrelated to chronic respiratory disease, and that there was
evidence in primary care records of asthma in life. Since
asthma may be a risk factor for chronic obstructive
pulmonary disease (COPD),15 mention of the latter was not
a reason for exclusion. We did not include cases with asthma
recorded in Part 2 of the certificate. Details of entry criteria
have been dealt with in a previous paper.16
Live hospital controls with a primary discharge diagnosis of
asthma (ICD 493) were used because of the difficulty in
selecting community controls with severe asthma and the
importance of controlling for severity as a potential con-
founding factor.16 Sampling frames were set up from
discharge lists obtained from the hospitals where asthma
deaths occurred (or the nearest hospitals to the community
deaths). One control was matched with each case firstly for
admission date within 6 months of the date of death (index
date) and then age (within 5 years and under age 65 years).16
Ethics approval was obtained from the South Thames
Multicentre Research Ethics Committee and local research
ethics committees.
Data collection and extraction
Service use data based on any mention in primary care
records in the previous 5 years were extracted in the
academic department, blind to case-control status from
photocopied and anonymised primary care records. Data
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beyond the 5 years were extracted non-blind in the practice.
These were ever mentioned COPD, family history of asthma,
evidence of atopy (eczema or hay fever), major non-
respiratory illness, obesity, smoking, and psychosocial fac-
tors.16 With respect to previous hospital admissions for
asthma, hospital records were used to validate the discharge
diagnosis, the length of hospital stay, and the exclusion of
the index admission (where appropriate). This could not be
done totally blind to status.
Use of primary and secondary care services
The use of medical service factors are listed in box 1. Data for
5 years before the index date were analysed as the year
immediately before the event and 4 years before that. For
recording of lung function and prescription of asthma drugs,
we further divided the time period in the last year into the
3 months before the index date and the 9 months before
that. When more than one lung function test was taken at a
single consultation it was counted as ‘‘one occasion’’ and
self-reporting was not taken into account.
Statistical methods
Data were analysed by fitting a series of conditional logistic
regression models in Stata (Stata Statistical Software Release
5.0, Stat Corporation, College Station, Texas, USA). Selected
variables that were significantly associated (p,0.05) with
asthma death in the preliminary analysis were then entered
into the same model along with sex in order to investigate
independent effects. After mutual adjustment, other vari-
ables were added to the model to adjust for markers of
asthma severity (such as co-morbidity with COPD, age of
asthma onset, prescription of home oxygen, and mention of
wheelchair), asthma drugs (prescription of systemic steroids
and antibiotics in the 3 months before the index date and
short acting bronchodilators in the 1–5 years before the index
date), and potential confounding factors (such as obesity,
social and psychological factors). We did not adjust for the
prescription of inhaled steroids as, in our previous analysis,17
they were not significantly associated with asthma death.
However, we did investigate their effects as a potential
confounder in sensitivity analyses. Finally, interaction terms
were added one at a time to investigate whether associations
differed in magnitude and/or direction between age groups
(,45, >45).
The results are presented as odds ratios and approximate
95% confidence intervals (based on the t distribution).
Statistical significance was assessed using the likelihood
ratio test. For continuous variables where odds ratios were
calculated on the grouped data for presentation, the overall p
values were performed based on the continuous data. If age
at asthma onset was recorded only as ‘‘in childhood’’ (as it
was for 4.4% of subjects), this was assumed to be 6 years—
that is, the median value for those with specified ages under
18 years.
The methods used for our investigation of prescribed drugs
and asthma are described in another paper.17 As already
reported, subsequent to the analysis we found that a
proportion of controls had been coded for prescribed drugs
that related to the index admission or beyond.17 Although
this will have affected the coding of systemic steroids and
antibiotic prescription in the previous 0–3 months, short
acting bronchodilator prescription in the 1–5 year period
should be unaffected by coding errors close to the index date.
The effect of using an alternative adjustment for asthma
drugs informed by results from our previous paper17 but
based solely on prescription in the previous 4–12 months and
1–5 years was also investigated.
RESULTS
Cases and controls
We identified 681 asthma deaths; 149 (22%) were excluded
because of missing records (n=82, 12%), miscoding (n=33,
5%), refusal or non-response from general practitioners
(n=10, 1%), time constraints (n=18, 3%), and non-resident
cases (n=6, 1%). Of the remaining 532 deaths, 293 (55%)
died in the community.16
The median age was 53 years (interquartile range (IQR)
40–59) for cases and 53 years (IQR 40–58.5) for controls; 60%
of cases and 64% of controls were female. Cases and controls
were similar in terms of family history of asthma (25% v
24%), evidence of atopy (39% v 41%), history of smoking
(58% v 59%), and major non-respiratory illness (44% v 43%).
Cases were more likely to have had an earlier age of asthma
onset (median age 30 years for cases v 33 years for controls,
p=0.02), to have had mention of COPD (42% v 35%,
p=0.005), and to be recorded by their general practitioner
as obese (31% v 25%, p=0.02). Occupation was mentioned
for 91 cases and 120 controls and, of these, similar
proportions were in manual occupations (cases 46%, controls
48%).16
Box 1 Medical care factors investigated
Medical care factors mentioned in primary care records:
N All practice contacts (excluding requests for prescrip-
tions)
N Respiratory consultations (including upper respiratory
tract infections)
N Home visits
N Home visits for respiratory illness
N Visits to a primary care based asthma clinic
N Use of home nebuliser
N Asthma drug non-compliance
N Poor inhaler technique
N Repeated non-attendance for asthma care
N Peak expiratory flow (PEF) recordings (excluding self-
recording)
N Forced expiratory volume in 1 second (FEV1) record-
ings
N Prescription of systemic steroids, short acting broncho-
dilators, and antibiotics (both on paper and electronic)
N Use of home oxygen
N Wheelchair use
Secondary care factors mentioned in primary care
records:
N Outpatient attendance (from hospital letters to general
practitioners)
N Acute asthma admissions (validated against hospital
records)
N Inpatient days for asthma admission (validated against
hospital records)
N Accident and emergency department attendance for
asthma
N PEF recordings (from hospital letters to general
practitioners and excluding self-recording)
N FEV1 recordings (from hospital letters to general
practitioners)
N Prescription of systemic steroids, short acting broncho-
dilators, and antibiotics (in discharge and outpatient
letters)
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Use of primary care services
The mean (SD) length of time between the last general
practice contact and the index date was 86.5 (156.5) days for
cases and 48.3 (82.5) days for controls (p,0.001, table 1).
Subtracting length of stay prior to death for cases dying in
hospital had little effect (84.4 (156.7) days v 48.3 (82.5) days,
p,0.001). Cases had significantly fewer general practice
contacts (odds ratio 0.90, 95% confidence interval (CI)
0.84 to 0.98, p=0.009, per five contacts) and respiratory
consultations (0.85 (95% CI 0.75 to 0.96) p=0.006 per five
consultations) in the last year. Conversely, cases had
significantly more home visits in the last year for respiratory
illness (95% CI 1.12 (1.04 to 1.20) p,0.001 per visit) and for
non-respiratory illness (1.19 (95% CI 1.08 to 1.32) p,0.001
per visit).
In the year before the index date, 93% of patients with a
home visit also had two or more recorded surgery visits. The
proportion with a prescription of short acting bronhodilators
Table 1 Use of general and asthma services in primary care by cases (n = 532) and control subjects (n = 532)
1 year before index date 1+ to 5 years before index date
Cases Controls Odds ratio 95% CI Cases Controls Odds ratio 95% CI
Use of general services
Mean (SD) no of days since last
practice contact
86.5 (156.5)
n = 528
48.3 (82.5)
n = 526
1.09*** per
month (30 days)
1.05 to 1.13 NA NA NA NA
Mean (SD) no of general practice
contacts
9.8 (8.8)
n = 529
11.1 (8.6)
n = 529
0.90** per
5 GP contacts
0.84 to 0.98 30.6 (24.5)
n = 528
34.0 (25.9)
n = 530
0.97* per
5 GP contacts
0.95 to 1.00
Mean (SD) no of respiratory
consultations
4.9 (5.1)
n = 528
5.8 (5.6)
n = 529
0.85** per
5 GP contacts
0.75 to 0.96 14.3 (14.3)
n = 527
14.2 (14.7)
n = 530
1.00 per
5 GP contacts
0.96 to 1.05
No of home visits for respiratory
illness (%)
*** ***
0 60.7 63.2 1.00 – 54.3 60.2 1.00 –
1–2 25.0 27.4 0.95 0.72 to 1.26 22.2 23.1 1.08 0.79 to 1.48
3+ 13.7 8.8 1.72 1.13 to 2.62 22.7 16.4 1.61 1.15 to 2.26
Missing 0.6 0.6 0.8 0.4
No of home visits for non-respiratory
illness (%)
***
0 76.7 83.8 1.00 – 64.3 64.8 1.00 –
1–2 14.7 10.7 1.56 1.06 to 2.29 20.9 23.7 0.93 0.69 to 1.25
3+ 8.1 4.9 1.85 1.10 to 3.11 14.1 11.1 1.30 0.89 to 1.89
Missing 0.6 0.6 0.8 0.4
Use of asthma services
Asthma clinic attended (%) 12.6 13.3 0.94 0.65 to 1.36 25.0 28.2 0.84 0.64 to 1.11
Prescription of home nebuliser (%) 36.5 32.3 1.22 0.94 to 1.58 35.2 29.1 1.34* 1.03 to 1.76
Prescription of home oxygen (%) 12.0 5.1 2.73*** 1.67 to 4.46 10.0 4.5 2.64*** 1.53 to 4.56
Mention of wheelchair (%) 3.6 1.5 2.38* 1.04 to 5.44 3.9 1.1 3.58** 1.44 to 8.88
Disability allowance application (%) 7.3 9.8 0.72 0.46 to 1.14 13.7 13.2 1.06 0.74 to 1.51
Asthma drug non-compliance (%) 6.4 6.4 1.00 0.61 to 1.65 13.5 12.0 1.14 0.79 to 1.65
Poor inhaler technique (%) 6.2 5.5 1.16 0.67 to 2.00 11.1 9.8 1.17 0.79 to 1.73
Asthma repeated non-attendance (%) 4.5 3.2 1.40 0.75 to 2.60 9.4 5.8 1.74* 1.08 to 2.83
Odds ratios and p values calculated using conditional logistic regression, ignoring the missing and unknown categories.
Odds ratios are adjusted for sex.
*p,0.05, **p,0.01, ***p,0.001.
Table 2 Use of asthma services in secondary care by cases (n = 532) and controls (n = 532)
1 year before index date 1+ to 5 years before index date
Cases Controls Odds ratio 95% CI Cases Controls Odds ratio 95% CI
No of outpatient appointments for
asthma (respiratory or general)
0 64.7 62.0 1.00 – 52.4 53.2 1.00 –
1–2 16.2 19.0 0.83 0.60 to 1.14 13.2 14.3 0.93 0.64 to 1.34
3+ 19.2 19.0 0.98 0.71 to 1.35 34.4 32.5 1.07 0.82 to 1.40
No of acute asthma admissions
0 64.8 65.0 1.00 – 58.8 57.0 1.00 –
1–2 22.6 24.4 0.92 0.68 to 1.25 22.2 22.9 0.93 0.69 to 1.27
3–4 7.3 7.7 0.93 0.58 to 1.49 6.6 9.6 0.67 0.43 to 1.07
5+ 5.3 2.8 1.83 0.97 to 3.46 12.4 10.5 1.16 0.77 to 1.74
No of days admitted for asthma
0 64.8 65.0 1.00 – 58.8 57.0 1.00 –
1–7 13.0 14.7 0.88 0.61 to 1.28 11.8 12.8 0.90 0.62 to 1.33
8–14 7.0 8.8 0.77 0.48 to 1.22 8.1 10.3 0.76 0.49 to 1.17
15+ 15.2 11.5 1.36 0.93 to 1.98 21.1 19.7 1.05 0.77 to 1.44
Missing 0 0 0.2 0.2
No of A&E attendances for asthma
0 93.4 94.5 1.00 – 92.3 95.1 1.00 –
1–2 5.5 5.1 1.10 0.64 to 1.88 7.0 4.3 1.61 0.94 to 2.74
3+ 1.1 0.4 2.94 0.59 to 14.6 0.8 0.6 1.34 0.29 to 6.08
Data presented as percentages.
Odds ratios and p values for trend calculated using conditional logistic regression, ignoring the missing and unknown categories.
Odds ratios are adjusted for sex.
*p,0.05, **p,0.01 , ***p,0.001 (trend).
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in the 1–5 years before index date was only slightly higher
among those with one or more home visits in the last year
(91% (420/461) v 86% (511/597)). However, this difference
was more pronounced among cases (95% (226/239) v 87%
(251/290)) than controls (87% (194/222) v 85% (260/307)).
Use of asthma services in primary care
In the year before the index date only 13% of cases and 13%
of controls had evidence of attending a formal primary care
based asthma clinic (table 1). In the 4 years before that,
repeated non-attendance for asthma care was more com-
monly recorded in the notes of cases than controls (odds ratio
1.74, 95% CI 1.08 to 2.83, p=0.02) as was possession of a
home nebuliser (1.34 (95% CI 1.03 to 1.76), p=0.03). In the
last year these associations were less marked and not
statistically significant (p.0.05). In the last year and in the
4 previous years, more cases than controls had mention of
wheelchair (3.6% v 1.5% in the last year) and home oxygen
(12.0% v 5.1% in the last year). Mentions of other relevant
aspects of health behaviour including asthma drug non-
compliance and poor inhaler technique were similar in cases
and controls. The findings on asthma drugs in this case-
control study are the subject of another paper.17
Use of asthma services in secondary care
Approximately one third of cases (37%) and controls (33%)
had no history of asthma admission or outpatient consulta-
tions for asthma in the previous 5 years (table 2). Only 55%
of both groups attended hospital outpatients in the last five
years and attendance was comparable both in the final year
and in the four years prior. In the last year 35% of both
groups were admitted to hospital on one or more occasions
with asthma; in the four years prior to that, 41% of cases and
43% of controls were admitted. Furthermore, in the last five
years, cases and controls also had similar patterns of in-
patient days for acute asthma (median 20 days for cases and
15 days for controls, excluding those with no admissions). In
the same time period only 12% of cases and 10% of controls
had records of accident and emergency attendance in their
primary care notes.
Lung function measurements
There was no significant difference between cases and
controls in the number of occasions when FEV1 was
measured in either primary or secondary care (table 3). In
primary care, cases had significantly fewer peak expiratory
flow (PEF) recordings than controls in the final 3 months
and also in the 9 months before that. In the same periods,
mentions of PEF recording in outpatient and discharge letters
were also fewer in cases than controls, although not
significantly (table 3).
The final model
The final model (table 4) is based on the significant findings
of the preliminary analyses (adjusted for sex) of medical
service use factors in the year before the index date and PEF
recording in the last 3 months. In the first column the odds
ratios are presented with adjustment for sex. In the second
they are additionally adjusted for each other, with all three
factors (number of GP contacts (excluding home visits) and
number of home visits, both in the previous year, and the
number of PEF measurements taken in the final 3 months)
remaining significantly associated with the risk of asthma
death. Odds ratios suggest that, in the year before the index
date, an additional five general practice contacts (excluding
home visits) were associated with an 18% lower risk of
asthma death, an additional home visit with a 14% higher
risk, and an additional PEF taken in the last 3 months was
associated with a 17% lower risk. In the third column,
adjustment for markers of asthma severity (COPD, age of
asthma onset, prescription of home oxygen and mention of
wheelchair in the previous year) and obesity had only a small
Table 3 Associations between asthma deaths and PEF and FEV1 monitoring in primary and secondary care in cases (n = 532)
and controls (n = 532)
3 months before index date 4–12 months before index date 1+ to 5 years before index date
Cases Controls
Odds
ratio 95% CI Cases Controls
Odds
ratio 95% CI Cases Controls
Odds
ratio 95% CI
Primary care
No of occasions PEF
recorded
*** *
0 77.8 63.2 1.00 – 60.3 54.9 1.00 – 32.9 27.4 1.00 –
1–5 22.0 34.8 0.50 0.38 to 0.67 34.4 37.4 0.83 0.64 to 1.07 39.1 41.2 0.78 0.58 to 1.06
6–10 0.2 1.9 0.09 0.01 to 0.70 4.1 6.4 0.59 0.34 to 1.02 13.9 15.2 0.75 0.51 to 1.11
10+ 0 0.2 1.1 1.3 0.78 0.26 to 2.33 14.1 16.2 0.70 0.46 to 1.04
No of occasions FEV1
recorded
0 99.6 99.1 1.00 – 99.1 99.2 1.00 – 98.5 98.3 1.00 –
1–5 0.4 0.9 0.41 0.08 to 2.10 0.9 0.8 1.23 0.33 to 4.59 1.5 1.7 0.90 0.35 to 2.32
Secondary care
No of occasions PEF
recorded in outpatients/
discharge letters
0 88.0 85.9 1.00 – 78.9 73.5 1.00 – 58.1 58.1 1.00 –
1–5 12.0 14.1 0.82 0.57 to 1.19 19.9 24.8 0.75 0.56 to 1.00 28.6 28.8 0.99 0.75 to 1.31
6–10 0 0 1.1 1.3 0.83 0.28 to 2.47 7.5 7.7 0.96 0.61 to 1.52
10+ 0 0 0 0.4 5.8 5.5 1.09 0.63 to 1.91
No of occasions FEV1
recorded
0 95.1 94.4 1.00 – 88.5 88.2 1.00 – 75.8 75.2 1.00 –
1–5 4.9 5.6 0.87 0.50 to 1.50 11.5 11.8 0.97 0.66 to 1.43 19.0 21.2 0.90 0.66 to 1.23
6+ 0 0 5.3 3.6 1.46 0.80 to 2.65
Data presented as percentages.
Odds ratios from conditional logistic regression are adjusted for sex.
*p,0.05, **p,0.01 , ***p,0.001 (trend).
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effect on these three apparently independent associations.
Further adjustment for prescription of systemic steroids (in
the previous 3 months), antibiotics (in the previous
3 months), short acting b agonists (in the previous 1–
5 years), and the significant psychosocial factors found in a
previous analysis of these data16 made little difference to
associations with GP contact and home visits. However,
adjustment for asthma drugs led to an increase in the odds
ratio for PEF (0.87 (95% CI 0.78 to 0.98)) and, with the
addition of psychosocial factors, the association just lost
statistical significance (0.89 (95% CI 0.78 to 1.01); p=0.06).
For GP contact the association with asthma death differed
significantly between age groups (p=0.015). Odds ratios
were 0.65 (95% CI 0.52 to 0.82) for those under 45 years of
age and 0.88 (95% CI 0.77 to 1.00) for those aged >45 years.
This suggests that, in the year before the index date, an
additional five general practice contacts (excluding home
visits) were associated with a 35% lower risk of asthma death
in the younger age group and only a 12% lower risk in the
older age group. There was no evidence of any difference in
association between age groups for peak flow (p=0.20) or
home visits (p=0.35).
Sensitivity analyses
We considered the possibility of bias stemming from the use
of hospital cases that would have been outside the primary
care system during their period of stay before death. Of the
236 (44%) cases that died in hospital, 36 had been in hospital
for more than seven whole days. Excluding these subjects
from the model presented in column 4 of table 4 had little
effect on associations with GP contact (0.80 (95% CI 0.71 to
0.90)), home visits (1.11 (95% CI 1.04 to 1.19)), or PEF (0.90
(95% CI 0.79 to 1.02)).
We also investigated the effect of using an alternative
adjustment for asthma drug prescription by including age
group (,45, 45–64) specific terms for oral steroids in the
previous 4–12 months, antibiotics in the previous 4–
12 months, and short acting bronchodilators in the previous
1–5 years. This had little effect on associations with GP
contact (0.81 (95% CI 0.72 to 0.92) per five contacts), home
visits (1.10 (95% CI 1.03 to 1.18) per visit), and PEF (0.85
(95% CI 0.75 to 0.96) per occasion). The return to significance
of the association with PEF may simply reflect the lack of
asthma drug data in the new model for the period of
observation (0–3 months). However, the association with GP
contact no longer differed significantly between age groups
(0.70 (95% CI 0.55 to 0.89) for subjects aged under 45 years
and 0.85 (95% CI 0.74 to 0.99) for those aged 45 and over
(p=0.16). These results were virtually unchanged when we
added age group (,45, 45+) specific terms for the prescrip-
tion of inhaled steroids in the 1–5 years before the index
date.
When we investigated the effect of adding prescription of
inhaled steroids in the 3 months before the index date to the
model presented in column 4 of table 4, the results were little
changed although the association with PEF recordings just
returned to statistical significance (OR 0.88 (95% CI 0.78
to1.00); p=0.04).
DISCUSSION
This case-control study is by far the largest yet reported, was
population based, and included older subjects up to 65 years
of age, making it the most representative of severe asthma
and asthma deaths. It included asthma deaths with
important co-morbidities such as COPD,15 since these are
likely to increase the risk of death. The data were largely
extracted by an unbiased method blind to case-control status.
Shortcomings of primary care records such as lack of
standardisation in diagnoses and in the recording of patient
reported symptoms should have equally affected cases and
controls. The low level of accident and emergency attendance
in both cases and controls may be due to under-reporting in
general practice records. It was difficult to assess whether
patients possessed self-management plans (symptom or PEF
based) as these are not generally recorded in primary care
records. Controls were only drawn from hospitals, but our
cases and controls were well balanced in terms of age, sex
and recent asthma admission, a possible marker of asthma
severity.12 18 Furthermore, possible bias due to length of stay
before death for cases dying in hospital appeared to have little
impact on the results.
Other investigators have used asthma admission in the
year before death, treatment with three or more classes of
drugs, and recent courses of oral steroids as markers of
asthma severity.18–20 We found little difference in recent
asthma admissions whereas systemic steroids were pre-
scribed less frequently for cases.17 Lung function was not
measured consistently and could not be used as a marker of
severity; 41% of cases and 30% of controls had no mention of
PEF or FEV1 recordings in the last year. More mentions of
COPD and earlier age of asthma onset suggested that cases
had more severe disease than controls. These markers of
severity along with obesity, wheelchair use, home oxygen
Table 4 Associations between asthma death and use of medical services factors (n = 1052)
Odds ratio (95% CI)
adjusted for sex
Mutually adjusted odds
ratio (95% CI) also
adjusted for sex
Mutually adjusted odds
ratio (95% CI) also
adjusted for sex
and COPD`1
Mutually adjusted odds
ratio (95% CI) also
adjusted for sex, drugs,
COPD`1 and
psychosocial factors
No of GP contacts in the previous year
(excluding home visits)
Per 5 contacts 0.82*** (0.75 to 0.89) 0.82*** (0.74 to 0.91) 0.79*** (0.71 to 0.88) 0.82 *** (0.73 to 0.92)
No of home visits in the previous year
Per visit 1.11*** (1.05 to 1.17) 1.14*** (1.08 to 1.21) 1.12*** (1.06 to 1.19) 1.12 *** (1.05 to 1.19)
No of PEF measurements in the previous
3 months
Per occasion PEF taken 0.80*** (0.72 to 0.88) 0.83*** (0.74 to 0.92) 0.83*** (0.74 to 0.93) 0.89 (0.78 to 1.01)
Adjusted for the other two medical service factors in the table.
`COPD defined as mention of COPD, COAD, chronic bronchitis or emphysema.
1Also adjusted for obesity, age of onset (including missing data), prescribed home oxygen in the previous year and mention of wheelchair in the previous year.
Drugs are prescription of systemic steroids in the previous 3 months, antibiotics in the previous 3 months, and short acting b agonists in the previous 1–5 years.
Psychosocial factors are financial/employment problems, drug/alcohol abuse, anxiety/prescribed antidepressants, sexual problems, psychosis, learning difficulties and
repeated non-attendance/poor inhaler technique.
*p,0.05, **p,0.01, ***p,0.001 (likelihood ratio test).
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prescription, systemic steroid, short acting bronchodilator
and antibiotic use were adjusted for in the analyses.
The main finding of this study was the lower rate of
consultations in primary care by cases compared with
controls, even after controlling for severity and psychosocial
factors and irrespective of the greater number of home visits.
This association appeared to be slightly stronger in those aged
under 45 years, a group that comprised few cases (7%) with
co-existing COPD, although any difference in the association
by age group may be explained, at least in part, by age related
differences in the associations between asthma death and
prescribed drugs, in particular antibiotics (data not shown).
The greater use of home visits among cases suggests that
their disease could have been more severe (acutely, chronic-
ally, or both). Alternatively, it could mean that these patients
were not using preventive therapy as effectively. This is
supported by the slightly higher proportion of cases with a
prescription for short acting bronchodilators in the previous
1–5 years.17 However, their significantly greater use of home
visits for non-respiratory illness in the last year might
indicate that these cases were unable to use services
‘‘appropriately’’ due to other factors. While cases were more
likely to have co-existent COPD, the associations with asthma
death persisted after adjustment for this.
The negative association with PEF recordings dropped just
below the 5% significance level when we additionally
adjusted for psychosocial factors in the final model
(table 4). Nevertheless, fewer PEF recordings in cases
suggests that lack of monitoring may be associated with
inadequate asthma management, in line with the findings
from confidential enquiries into asthma deaths.2 4 6 8
Prescription of systemic steroids in the last 3 months was
also positively associated with PEF recording in both cases
and controls over the same time period (data not shown).
However, this did not appear to explain fully the association
between lack of PEF recording and asthma death (table 4).
Moreover, our information on drugs is not without bias due
to problems in coding around the index date,17 and tells us
nothing about dosage or whether prescription represented
long term treatment or a change in treatment in the short
term. The possibility that PEF recording is associated with a
lower risk of asthma death because it leads to more
appropriate immediate treatment cannot be discounted.
When psychosocial factors were included in our analysis,
they did not explain the association between practice
contacts and asthma death. Although a higher proportion
of controls had mention of anxiety,16 this did not appear to
explain differences in service use. However, there are some
patient factors that we were unable to elicit because they are
not generally recorded in primary care records. It may be that
some vulnerable patients have a poor perception of the
severity of their acutely worsening airflow obstruction and/or
their level of self-monitoring may be low or non-existent.
Some patients may panic and seek treatment more readily,
while others may be in a state of denial and delay treatment.
All these factors could have an impact on the use of medical
services, particularly in the short term.
This study has found a number of associations between
medical service use and mortality but, because it is
observational in nature, it cannot in itself satisfactorily
resolve questions of cause and effect or underlying mechan-
isms. The resolution of such questions will require more
detailed studies using purpose built methods—including
clinical trials where appropriate—rather than relying, as we
have done, on routine records. Nevertheless, we conclude
that asthma death is associated with lesser use of primary
care services and that a better understanding of both the
practice and patient factors involved may offer possibilities
for reducing asthma death.
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Combination antibiotic susceptibility testing in CF: disappointing clinical results
m Aaron SD, Vandemheen KL, Ferris W, et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic
fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 2005;366:463–
71
P
atients with cystic fibrosis (CF) are often colonised with multiresistant organisms. In
vitro data suggest that bactericidal activity may result from antibiotic synergy even if
species are resistant to individual agents on routine resistance testing. Simultaneously
testing the bactericidal activity of two or more antibiotics (multiple combination bactericidal
antibiotic testing, MCBT) is one approach that has been suggested to combat this problem.
This multicentre, prospective, double blind, randomised controlled trial investigated the in
vivo effects of selecting antibiotics for exacerbations of CF, based on MCBT versus
conventional sensitivity testing. Sputum was tested every 3 months for up to 4 years from
251 patients with CF over 12 years of age who were chronically infected with multiresistant
organisms. Both testing methods were used for each sample. Using the results,
combinations of two antibiotics with or without nebulised tobramycin were recommended
by two separate investigators—one using the MCBT results and the other the conventional
sensitivity results.
One hundred and thirty two patients developed exacerbations and were randomised; 64
received MCBT directed therapy and 68 conventionally guided therapy. The primary end
point was time to the next exacerbation and secondary end points were changes in sputum
bacteria density, FEV1, FVC, dyspnoea, white cell count, C reactive protein and erythrocyte
sedimentation rate, and length of hospital stay. There was no difference in the primary end
point between the two groups (85 days in the MCBT group v 79 days in the conventional
group). The reduction in white cell count was greater in the MCBT group (p = 0.02) but
hospital stay was 3 days longer (p = 0.03). Otherwise, no significant differences were
observed.
Caution must be taken when judging the value of tests which appear useful in vitro: this
may not necessarily translate to clinical benefit.
J Holme
Specialist Registrar, University Hospital of North Staffordshire, Stoke-on-Trent, UK;
jayne.holme1@btinternet.com
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